Search
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalThe Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. … Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: 2-chloro-N-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: P-glycoprotein substrates, Sodium-Glucose Transporter 2 InhibitorsButamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawn[A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics. … Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate.
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigationalMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … cutaneous T-cell lymphoma.
Categories: Chemokine Receptor Type 4 Interaction, Chemokine Receptor Type 4 InteractionsCupric oxide
go.drugbank.com/drugs/DB11134ApprovedCupric oxide is used as a precursor in many copper-containing products such as wood preservatives and ceramics. … Cupric oxide, or copper (II) oxide, is an inorganic compound with the chemical formula CuO.
Mixtures: Marnatal F, Ribotin-EDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[A180478] As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in … It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: DUPIXENT® 300MG, DUPIXENT® 200MGTasonermin
go.drugbank.com/drugs/DB11626ApprovedIt was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma
Suramin
go.drugbank.com/drugs/DB04786InvestigationalA polyanionic compound with an unknown mechanism of action. … Suramin is manufactured by Bayer in Germany as Germanin®.
Dacarbazine
go.drugbank.com/drugs/DB00851ApprovedInvestigationalAn antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564).
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexSynonyms: 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide, 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamideDolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigationalDolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). … [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named
Mixtures: TRIUMEQ® 50 MG / 600 MG / 300 MGCategories: MATE 1 Inhibitors, P-glycoprotein substrates